Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, Ginis J, Perez JL. Senders S, et al. Among authors: jansen ku. Pediatr Infect Dis J. 2016 May;35(5):548-54. doi: 10.1097/INF.0000000000001072. Pediatr Infect Dis J. 2016. PMID: 26835974 Clinical Trial.
Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.
McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, Mason K, Jiang HQ, Zhu D, Mininni TL, Zlotnick GW, Hoiseth SK, Jones TR, Pride MW, Jansen KU, Anderson AS. McNeil LK, et al. Among authors: jansen ku. Vaccine. 2009 May 26;27(25-26):3417-21. doi: 10.1016/j.vaccine.2009.01.075. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200847
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.
Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. Murphy E, et al. Among authors: jansen ku. J Infect Dis. 2009 Aug 1;200(3):379-89. doi: 10.1086/600141. J Infect Dis. 2009. PMID: 19534597
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. Jiang HQ, et al. Among authors: jansen ku. Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7. Vaccine. 2010. PMID: 20619376
Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.
Ala'aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, Bayliss CD, Turner DP, Neal KR, Hoiseth SK, Jansen KU, Anderson AS. Ala'aldeen DA, et al. Among authors: jansen ku. Vaccine. 2010 Nov 10;28(48):7667-75. doi: 10.1016/j.vaccine.2010.09.038. Epub 2010 Sep 25. Vaccine. 2010. PMID: 20875489
New frontiers in meningococcal vaccines.
Anderson AS, Jansen KU, Eiden J. Anderson AS, et al. Among authors: jansen ku. Expert Rev Vaccines. 2011 May;10(5):617-34. doi: 10.1586/erv.11.50. Expert Rev Vaccines. 2011. PMID: 21604983 Free article. Review.
Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis.
Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, Nuñez L, Carriere M, Singer C, Dilts DA, Jansen KU. Anderson AS, et al. Among authors: jansen ku. J Infect Dis. 2012 Jun;205(11):1688-96. doi: 10.1093/infdis/jis272. Epub 2012 Apr 2. J Infect Dis. 2012. PMID: 22474033 Free PMC article.
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators. Richmond PC, et al. Among authors: jansen ku. Lancet Infect Dis. 2012 Aug;12(8):597-607. doi: 10.1016/S1473-3099(12)70087-7. Epub 2012 May 7. Lancet Infect Dis. 2012. PMID: 22569484 Clinical Trial.
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, Perez JL. Marshall HS, et al. Among authors: jansen ku. Pediatr Infect Dis J. 2012 Oct;31(10):1061-8. doi: 10.1097/INF.0b013e31826327e4. Pediatr Infect Dis J. 2012. PMID: 22718089 Clinical Trial.
249 results